Abstract
The Tuberculosis Network European Trials Group (TBNET) is the largest clinical research organisation in Europe. Educational activities include the TBNET Academy and the European Advanced Course in Clinical Tuberculosis. Four of their publications are reviewed to show how the clinical management of tuberculosis is changing.
Key points
Most tuberculosis (TB) in contacts is found at their first visit.
In contacts of pulmonary TB patients, the likelihood of later TB is ≤3%.
Genetic tests can indicate when another antimycobacterial drug in the same class might be effective (e.g. rifabutin when there is rifampicin resistance or which injectable to choose).
The short-course “Bangladesh” regimen can only be rarely used in Europe.
Treatment completion in multidrug-resistant TB should not be included as a successful outcome.
Abstract
Learn about @TBnet_EU, the largest clinical research organisation in Europe http://ow.ly/NHTh30e53KE
Footnotes
Conflict of interest None declared.
- Copyright ©ERS 2017
Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.